Document:

Exhibit 10.17

 

 

5875 Green Valley Circle, Suite 100

Culver City, CA 90230

Phone: 984.377.3737

Fax: 888.534.6531

 

October 20, 2016

 

Jonathan Cotliar, M.D.

 

Re:         Offer of
Employment

 

Dear Jonathan,

 

On
behalf of Science 37, Inc. (“Science 37”), I am pleased to offer you employment in the position of Vice President
of Medical Affairs, reporting to Belinda Tan, M.D., Ph.D., Chief Medical Officer. Your responsibilities in this position would include
but not be limited to: advising on trial execution and overseeing trial operations from a medical and investigator standpoint; serving
as Principal Investigator in Dermatology trials, as needed; responding to sponsor questions regarding trial feasibility; and helping establish
strategic partnerships. This letter sets out the terms of your employment with Science 37, which will start on November 1, 2016 at
50% time and on January 1, 2017 at 100% time, should you accept this offer.

 

If you decide to join us,
for the period during which you are 50% time, your salary will be $10,000 per month. When you shift to 100% time, your salary will be
$20,000 per month, which annualizes to $240,000 per year, less applicable tax and other withholdings, paid in accordance with Science
37’s normal payroll practices. Future adjustments in compensation, if any, will be made by Science 37 in its sole and absolute discretion.
This position is an exempt position, which means you are paid for the job and not by the hour. Accordingly, you will not receive overtime
pay if you work more than 8 hours in a workday or 40 hours in a workweek.

 

In addition, you will be eligible
to participate in Science 37’s fringe benefit plans, including health insurance premium contributions, vacation program, and 401(k) retirement
savings plan in accordance with the benefit plan requirements, as long as your percent time is at least 80%. Science 37 may change its
benefit plans from time to time in accordance with applicable laws. You may also be eligible to participate in any incentive compensation
plan that may be established by Science 37 during your employment.

 

To support your relocation,
we will provide you with a one-time, upfront payment of $25,000 to reimburse you in advance for your relocation costs. Please submit all
receipts to ensure treatment of reimbursement. Any unused portion of the $25,000 relocation expense will be treated as taxable wages subject
to withholding of all applicable taxes.

 

As
the Vice President of Medical Affairs, we will provide you $7,500 annually for conferences that are mutually determined to further the
mission of Science 37 with the understanding that there will be some overlap between your professional interests in Dermatology and Science
37’s mission.

 

Subject to the approval of
Science 37’s Board of Directors, you will be granted an option to purchase 100,000 shares of Science 37 common stock in accordance
with Science 37’s Stock Option Agreement. Should the Board approve the grant, you will be required to sign the Science 37 Stock
Option Plan Agreement and your option will be subject to the terms and conditions of the same. Any option granted will vest over a period
of to be determined by Science 37’s Board of Directors.

 

    

    

    

 

Jonathan Cotliar, M.D.

October 20, 2016

Page 2

 

If you accept this offer,
your employment with Science 37 will be “at will.” This means it is not for any specific period of time and can be terminated
by you at any time for any reason. Likewise, Science 37 can terminate the employment relationship at any time, with or without cause or
advance notice. In addition, Science 37 reserves the right to modify your compensation, position, duties or reporting relationship to
meet business needs and use its managerial discretion in deciding on appropriate discipline.

 

This offer is contingent upon
you: 1) signing Science 37’s standard form of Employee Proprietary Information and Inventions Agreement (a copy of which is enclosed);
2) affirming that you have not been not been excluded, suspended, or debarred from participation in any Federal Health Care Program or
in Federal contracts; and 3) timely providing Science 37 with appropriate documents establishing your identity and right to work in the
United States.

 

This letter and the Employee
Proprietary Information and Inventions Agreement constitute the entire agreement between you and Science 37 regarding the terms and conditions
of your employment, and supersede all negotiations, representations or agreements, whether prior or contemporaneous, written or oral,
between you and Science 37 on this subject. The provisions of this agreement regarding “at will” employment may only be modified
by a document signed by you and an authorized representative of Science 37.

 

Jonathan, we look forward
to working with you at Science 37. This offer will remain open until October 31, 2016. Please sign and date this letter on the spaces
provided below to acknowledge your acceptance of Science 37’s offer on the terms set forth in this letter.

 

	 	
    Sincerely,

     

    Science 37, Inc.

 

	 	By	/s/ Noah Craft
	 	 	Noah Craft, M.D., Ph.D., D.T.M.H.
	 	 	Chief Executive Officer

 

I agree to and accept employment with Science 37 on the terms and conditions
set forth in this agreement. I affirm that I have not been excluded, suspended, or debarred from participation in any Federal Health Care
Program or in Federal contracts. I understand and agree that my employment with Company is at-will.

 

	Date:	11/14/16	 	/s/ Jonathan Cotliar, M.D.
	 	 	 	Jonathan Cotliar, M.D.NextPlay Technologies, Inc. 8-K

 

Exhibit
10.1

 

THE
EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS
AMENDED.

 

EXCHANGE
AGREEMENT

 

This
Exchange Agreement (this “Agreement”) is entered into as of July 15, 2021 (the “Effective Date”)
by and between Streeterville Capital, LLC, a Utah limited liability company (“Lender”), and NextPlay Technologies,
Inc., a Nevada corporation (f/k/a Monaker Group, Inc., a Nevada corporation) (“Borrower”). Capitalized terms
used in this Agreement without definition shall have the meanings given to them in the Transaction Documents (as defined below).

 

A.          Borrower previously sold and issued to Lender that certain Secured Promissory Note dated November 23, 2020 in the original principal
amount of $5,520,000.00 (the “Original Note”) pursuant to that certain Note Purchase Agreement dated November
23, 2020 by and between Lender and Borrower (the “Purchase Agreement,” and together with the Original Note
and all other documents entered into in conjunction therewith, the “Transaction Documents”).

 

B.          Subject to the terms of this Agreement, Borrower and Lender desire to partition a new Secured Promissory Note in the original
principal amount of $400,000.00 (the “Partitioned Amount”) from the Original Note and then cause the outstanding
balance of the Original Note to be reduced by an amount equal to the Partitioned Amount.

 

C.           Borrower and Lender further desire to exchange (such exchange is referred to as the “Note Exchange”) the Partitioned
Amount for 200,000 shares of the Borrower’s Common Stock, par value $0.00001 (the “Common Stock”, and
such 200,000 shares of Common Stock, the “Exchange Shares”), according to the terms and conditions of this
Agreement.

 

D.          The Note Exchange will consist of Lender surrendering the Partitioned Amount in exchange for the Exchange Shares, which will be
issued free of any restrictive securities legend.

 

E.           Other than the surrender of the Partitioned Amount, no consideration of any kind whatsoever shall be given by Lender to Borrower
in connection with this Agreement.

 

F.           Lender and Borrower now desire to exchange the Partitioned Amount for the Exchange Shares on the terms and conditions set forth
herein.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree
as follows:

 

1.           Recitals and Definitions. Each of the parties hereto acknowledges and agrees that the recitals set forth above in this
Agreement are true and accurate, are contractual in nature, and are hereby incorporated into and made a part of this Agreement.

 

2.           Partition.
Effective as of the date hereof, Borrower and Lender agree that the Partitioned Amount is hereby partitioned from the
Original Note. Following such partition of the Original Note, Borrower and Lender agree that the Original Note shall remain
in full force and effect, provided that the outstanding balance of the Original Note shall be reduced by an amount equal to
the Partitioned Amount. For avoidance of doubt, the rights, duties, obligations, remedies of Borrower and Lender, and other
terms and conditions of the Original Note shall remain unchanged upon the entering into of this Agreement, except with
respect to the reduction in the outstanding balance by the amount of the Partitioned Amount.

 

     

     

    

 

3.           Issuance of Shares. Pursuant to the terms and conditions of this Agreement, the Note Exchange shall occur with Borrower
delivering the Exchange Shares to Lender against Lender surrendering the Partitioned Note to Borrower on the Closing Date (as
defined below). Upon delivery of the Exchange Shares, the Partitioned Note shall be cancelled and all obligations of Borrower
under the Partitioned Note shall be deemed fulfilled. All Exchange Shares delivered hereunder shall be delivered via DWAC to Lender’s
designated brokerage account. Borrower agrees to provide all necessary cooperation or assistance that may be required to cause
all Exchange Shares delivered hereunder to become Free Trading (the first date on which all Exchange Shares become Free Trading,
the “Free Trading Date”). For purposes hereof, the term “Free Trading” means that (a) the
Exchange Shares have been cleared and approved for public resale by the compliance departments of Lender’s brokerage firm
and the clearing firm servicing such brokerage, and (b) such shares are held in the name of the clearing firm servicing Lender’s
brokerage firm and have been deposited into such clearing firm’s account for the benefit of Lender.

 

4.           Closing. The closing of the transaction contemplated hereby (the “Closing”) along with the delivery
of the Exchange Shares to Lender shall occur on the date that is mutually agreed to by Borrower and Lender by means of the exchange
by express courier and email of .pdf documents, but shall be deemed to have occurred at the offices of Hansen Black Anderson Ashcraft
PLLC in Lehi, Utah.

 

5.           Holding Period, Tacking and Legal Opinion. Borrower represents, warrants and agrees that for the purposes of Rule 144 (“Rule
144”) of the Securities Act of 1933, as amended (the “Securities Act”), the holding period of the
Partitioned Amonut and the Exchange Shares will include Lender’s holding period of the Original Note from November 23, 2020.
Borrower agrees not to take a position contrary to this Section 5 in any document, statement, setting, or situation. Borrower
agrees to take all action necessary to issue the Exchange Shares without restriction, and not containing any restrictive legend
without the need for any action by Lender; provided that the applicable holding period has been met. In furtherance thereof, prior
to the Closing, counsel to Lender may, in its sole discretion, provide an opinion that: (a) the Exchange Shares may be resold
pursuant to Rule 144 without volume or manner-of-sale restrictions; and (b) the transactions contemplated hereby and all other
documents associated with this transaction comport with the requirements of Section 3(a)(9) of the Securities Act. Borrower represents
that it is not subject to Rule 144(i). The Exchange Shares are being issued in substitution of and exchange for and not in satisfaction
of the Partitioned Amount. The Exchange Shares shall not constitute a novation or satisfaction and accord of the Partitioned Amount.
Borrower acknowledges and understands that the representations and agreements of Borrower in this Section 5 are a material inducement
to Lender’s decision to consummate the transactions contemplated herein.

 

     2

     

    

 

6.            Borrower’s
Representations, Warranties and Agreements. In order to induce Lender to enter into this Agreement, Borrower, for
itself, and for its affiliates, successors and assigns, hereby acknowledges, represents, warrants and agrees as follows: (a)
Borrower has full power and authority to enter into this Agreement and to incur and perform all obligations and covenants
contained herein, all of which have been duly authorized by all proper and necessary action, (b) no consent, approval, filing
or registration with or notice to any governmental authority is required as a condition to the validity of this Agreement or
the performance of any of the obligations of Borrower hereunder, (c) no Event of Default has occurred under the Original Note
and any Events of Default that may have occurred thereunder have not been, and are not hereby, waived by Lender, (d) except
as specifically set forth herein, nothing herein shall in any manner release, lessen, modify or otherwise affect
Borrower’s obligations under the Original Note, (e) the issuance of the Exchange Shares is duly authorized by all
necessary corporate action and the Exchange Shares are validly issued, fully paid and non-assessable, free and clear of all
taxes, liens, claims, pledges, mortgages, restrictions, obligations, security interests and encumbrances of any kind, nature
and description, (f) Borrower has not received any consideration in any form whatsoever for entering into this Agreement,
other than the surrender of the Partitioned Amount, and (g) Borrower has taken no action which would give rise to any claim
by any person for a brokerage commission, placement agent or finder’s fee or other similar payment by Borrower related
to this Agreement.

 

7.            Lender’s Representations, Warranties and Agreements. In order to induce Borrower to enter into this Agreement, Lender,
for itself, and for its affiliates, successors and assigns, hereby acknowledges, represents, warrants and agrees as follows: (a)
Lender has full power and authority to enter into this Agreement and to incur and perform all obligations and covenants contained
herein, all of which have been duly authorized by all proper and necessary action, (b) no consent, approval, filing or registration
with or notice to any governmental authority is required as a condition to the validity of this Agreement or the performance of
any of the obligations of Lender hereunder, (c) Lender has taken no action which would give rise to any claim by any person for
a brokerage commission, placement agent or finder’s fee or other similar payment by Borrower related to this Agreement,
(d) Lender is not currently an affiliate of the Borrower and has not been an affiliate of the Borrower for the prior three months,
and (f) Lender, together with its affiliates, does not, and will not following the receipt of the Exchange Shares, beneficially
own more than 4.99% of the number of shares of Common Stock outstanding on the Effective Date. For purposes of Section 7(f), beneficial
ownership of Common Stock will be determined pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended.

 

8.            Governing Law; Venue. This Agreement shall be construed and enforced in accordance with, and all questions concerning the
construction, validity, interpretation and performance of this Agreement shall be governed by, the internal laws of the State
of Utah, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Utah or any
other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Utah. The provisions
set forth in the Purchase Agreement to determine the proper venue for any disputes are incorporated herein by this reference.
The parties agree that the Arbitration Provisions shall apply to any dispute that may arise between Borrower and Lender under
this Agreement. BORROWER HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

     3

     

    

 

9.           Arbitration of Claims. This Agreement shall be subject to the Arbitration Provisions.

 

10.         Counterparts. This Agreement may be executed in any number of counterparts with the same effect as if all signing parties
had signed the same document. All counterparts shall be construed together and constitute the same instrument. The exchange of
copies of this Agreement and of signature pages by facsimile transmission or other electronic transmission (including email) shall
constitute effective execution and delivery of this Agreement as to the parties and may be used in lieu of the original Agreement
for all purposes. Signatures of the parties transmitted by facsimile transmission or other electronic transmission (including
email) shall be deemed to be their original signatures for all purposes.

 

11.         Attorneys’ Fees. In the event of any arbitration or action at law or in equity to enforce or interpret the terms
of this Agreement, the parties agree that the party who is awarded the most money shall be deemed the prevailing party for all
purposes and shall therefore be entitled to an additional award of the full amount of the attorneys’ fees and expenses paid
by such prevailing party in connection with the arbitration, litigation and/or dispute without reduction or apportionment based
upon the individual claims or defenses giving rise to the fees and expenses. Nothing herein shall restrict or impair an arbitrator’s
or a court’s power to award fees and expenses for frivolous or bad faith pleading.

 

12.         No Reliance. Borrower acknowledges and agrees that neither Lender nor any of its officers, directors, members, managers,
equity holders, representatives or agents has made any representations or warranties to Borrower or any of its agents, representatives,
officers, directors, or employees except as expressly set forth in this Agreement and the Transaction Documents and, in making
its decision to enter into the transactions contemplated by this Agreement, Borrower is not relying on any representation, warranty,
covenant or promise of Lender or its officers, directors, members, managers, equity holders, agents or representatives other than
as set forth in this Agreement.

 

13.         Severability. If any part of this Agreement is construed to be in violation of any law, such part shall be modified to
achieve the objective of the parties to the fullest extent permitted and the balance of this Agreement shall remain in full force
and effect.

 

14.         Entire Agreement. This Agreement, together with the Transaction Documents, and all other documents referred to herein,
supersedes all other prior oral or written agreements between Borrower, Lender, its affiliates and persons acting on its behalf
with respect to the matters discussed herein, and this Agreement and the instruments referenced herein contain the entire understanding
of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein,
neither Lender nor Borrower makes any representation, warranty, covenant or undertaking with respect to such matters.

 

15.         Amendments. This Agreement may be amended, modified, or supplemented only by written agreement of the parties. No provision
of this Agreement may be waived except in writing signed by the party against whom such waiver is sought to be enforced.

 

     4

     

    

 

16.         Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and assigns. This Agreement or any of the severable rights and obligations inuring to the benefit of or to be performed
by Lender hereunder may be assigned by Lender to a third party, including its financing sources, in whole or in part. Borrower
may not assign this Agreement or any of its obligations herein without the prior written consent of Lender.

 

17.         Continuing Enforceability; Conflict Between Documents. Except as otherwise modified by this Agreement, the Original Note
and each of the other Transaction Documents shall remain in full force and effect, enforceable in accordance with all of its original
terms and provisions. This Agreement shall not be effective or binding unless and until it is fully executed and delivered by
Lender and Borrower. If there is any conflict between the terms of this Agreement, on the one hand, and the Original Note or any
other Transaction Document, on the other hand, the terms of this Agreement shall prevail.

 

18.         Time of Essence. Time is of the essence with respect to each and every provision of this Agreement.

 

19.         Notices. Unless otherwise specifically provided for herein, all notices, demands or requests required or permitted under
this Agreement to be given to Borrower or Lender shall be given as set forth in the “Notices” section of the Purchase
Agreement.

 

20.         Further Assurances. Each party shall do and perform or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

[Remainder
of page intentionally left blank]

 

     5

     

    

 

IN
WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first set forth above.

  

		BORROWER:
	 		
	 	NEXTPLAY TECHNOLOGIES, INC.
	 		
	 	By:	/s/ Bill Kerby
	 	Name:	Bill Kerby
	 	Title:	Co-CEO

 

	 	LENDER:
	 	 	 
	 	STREETERVILLE CAPITAL, LLC
	 	 	 
	 	By:	/s/
    John M. Fife 
	 	 	John M. Fife, President

 

[Signature
Page to Exchange Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}]]